GlaxoSmithKline to withdraw blood cancer drug from the US

Earlier this month, a late stage trial showed that the drug did not meet the goal of 'progression-free survival'.

Related Keywords

Sabine Luik , ,Thisismoney ,Money ,Moneymarkets ,